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Identification and characterization of small molecule inhibitors of porcine
reproductive and respiratory syndrome virus
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is the etiological agent of PRRS, an
economically significant disease of swine worldwide. PRRSV is poorly controlled by the currently available
vaccines, and alternative control strategies are needed to help prevent the continual circulation of the virus.
Previously, we developed a synthetic route for the natural compound atractylodinol and demonstrated anti-
PRRSV activity in vitro. However, the synthetic route was inefficient and the yield was poor. To identify
PRRSV inhibitors that could be synthesized easily and cost-effectively, we synthesized a series of
atractylodinol analogs and characterized their anti-PRRSV activity in vitro. A furan-substituted bis-enyne
subunit was found to be critical for PRRSV inhibition. Six analogs had potent inhibitory activity against
PRRSV with 50% inhibition concentration (IC50) of 0.4–1.4 μM and 50% cytotoxic concentration (CC50)
of 209–1537 μM in MARC-145 cells. Three of the most promising compounds also demonstrated significant
antiviral activity and low cytotoxicity in porcine macrophages. Inhibition of PRRSV in MARC-145 cells
occurred primarily at a post-entry step during PRRSV replication, between 4 and 12 h post-entry. These
results suggest that atractylodinol analogs are promising antiviral candidates that could augment current
PRRSV control strategies.
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Abstract	
	 Porcine	reproductive	and	respiratory	syndrome	virus		(PRRSV)	is	the	etiological	
agent	of	PRRS,	an	economically	significant	disease	of	swine	worldwide.	PRRSV	is	poorly	
controlled	by	the	currently	available	vaccines,	and	alternative	control	strategies	are	needed	
to	help	prevent	the	continual	circulation	of	the	virus.	Previously,	we	developed	a	synthetic	
route	for	the	natural	compound	atractylodinol	and	demonstrated	anti‐PRRSV	activity	in	
vitro.	However,	the	synthetic	route	was	inefficient	and	the	yield	was	poor.		To	identify	
PRRSV	inhibitors	that	could	be	synthesized	easily	and	cost‐effectively,	we	synthesized	a	
series	of	atractylodinol	analogs	and	characterized	their	anti‐PRRSV	activity	in	vitro.	A	
furan‐substituted	bis‐enyne	subunit	was	found	to	be	critical	for	PRRSV	inhibition.	Six	
analogs	had	potent	inhibitory	activity	against	PRRSV	with	50%	inhibition	concentration	
(IC50)	of	0.4‐1.4	μM	and	50%	cytotoxic	concentration	(CC50)	of	209‐1537	 M	in	MARC‐
145	cells.	Three	of	the	most	promising	compounds	also	demonstrated	significant	antiviral	
activity	and	low	cytotoxicity	in	porcine	macrophages.	Inhibition	of	PRRSV	in	MARC‐145	
cells	occurred	primarily	at	a	post‐entry	step	during	PRRSV	replication,	between	4	and	12	hr	
post‐entry.	These	results	suggest	that	atractylodinol	analogs	are	promising	antiviral	
candidates	that	could	augment	current	PRRSV	control	strategies.		
	
Keywords:		PRRSV;	antivirals;	atractylodinol	analogs	 	
	 3
Highlights	
 Developed	efficient	routes	for	synthesis	of	atractylodinol	analogs	that	inhibit	PRRSV	
replication	in	MARC‐145	cells	and	in	porcine	macrophages	
 Determined	the	presence	of	a	bis‐enyne	subunit	was	critical	for	antiviral	activity	
 Identified	six	analogs	of	atractylodinol	with	IC50	of	0.4‐1.4	M	in	vitro	
 Determined	inhibition	of	PRRSV	in	MARC‐145	cells	occurs	at	a	post‐entry	step	
during	virus	replication	
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1.	Introduction	
Porcine	reproductive	and	respiratory	syndrome	virus		(PRRSV)	is	the	etiological	agent	
of	PRRS,	an	economically	significant	disease	of	swine	worldwide.	PRRSV	causes	
reproductive	losses	from	abortions	and	stillbirths	in	pregnant	sows,	and	respiratory	
disease	in	growing	pigs,	resulting	in	an	estimated	$664	million	in	annual	costs	to	the	US	
pork	industry	(Collins	et	al.,	1992;	Holtkamp	et	al.,	2012;	Loula,	1991).	Although	a	number	
of	killed	and	attenuated	vaccines	are	available,	their	effectiveness	is	limited	due	to	the	high	
rate	of	variation	and	genetic	diversity	of	the	virus	(Kimman	et	al.,	2009;	Murtaugh	and	
Genzow,	2011;	Rose	et	al.,	2015).	In	addition,	PRRSV	is	capable	of	persisting	in	vivo	for	
months	after	the	initial	infection,	potentially	leading	to	the	occurrence	of	additional	
outbreaks	within	herds	(Allende	et	al.,	2000;	Wills	et	al.,	2003;	Wills	et	al.,	1997).	
Additional	strategies	for	PRRSV	prevention	and	control	include	biosecurity	and	
containment	measures.	However,	due	to	the	high	transmissibility	of	PRRSV,	the	virus	can	
quickly	spread	from	one	barn	and/or	farm	to	others	and	outbreaks	continually	occur.		
Antivirals	could	be	a	useful	complement	to	current	PRRSV	control	and	containment	
strategies.	In	the	past	few	years,	antivirals	against	PRRSV	have	been	described	in	the	
literature	that	include	microRNAs,	antisense	RNA,	immune	stimulators,	and	herbal	extracts	
(reviewed	in	Du	et	al.,	2017).	Many	of	the	antivirals	derived	from	herbs,	plants,	or	
mushrooms	are	used	in	traditional	Chinese	medicine,	and	many	have	been	shown	to	have	
antiviral	activity	against	a	wide	variety	of	viruses	(Mukhtar	et	al.,	2008).	Synthetic	
antivirals	such	as	epigallocatechin	gallate	(EGCG),	EGCG	plamitate,	and	ribavarin	were	
found	to	inhibit	PRRSV‐associated	cytopathic	effects	in	MARC‐145	cells	in	a	dose‐
dependent	manner	when	added	either	pre‐	or	post‐infection	with	100	TCID50	PRRSV	(Zhao	
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et	al.,	2014).	To	date,	few	studies	have	examined	anti‐PRRSV	activity	in	vivo.	In	one	study	
(Gao	et	al.,	2013),	treatment	of	pigs	with	extracts	of	Cryptoporus	volvatus,	a	polypore	
fungus,	resulted	in	reduction	in	virus	replication	and	clinical	symptoms	as	compared	to	the	
control	group.	However,	the	treatment	protocol	included	twice	daily	intramuscular	
injections	of	the	extract	for	eight	days,	which	is	not	practical	for	field	applications.		
Nonetheless,	the	results	demonstrate	the	potential	of	antivirals	for	reducing	the	virological	
and	clinical	burden	of	PRRSV	infection	in	vivo.		
One	impediment	to	the	use	of	antivirals	for	treatment	of	PRRSV	is	the	cost	of	
treatment.	Many	of	the	natural	compounds	with	anti‐PRRSV	activity	are	difficult	and/or	
costly	to	extract	in	large	quantities.		In	order	to	feasibly	produce	large	amounts	of	anti‐
PRRSV	compounds	for	in	vivo	application,	it	is	therefore	necessary	to	identify	potent	anti‐
PRRSV	compounds	that	can	be	generated	easily	and	cost‐effectively.		The	goal	of	the	
present	study	was	to	synthesize	and	evaluate	small	molecule	inhibitors	of	PRRSV	with	the	
potential	for	large‐scale	production.	Toward	that	end,	we	were	especially	interested	in	
identifying	compounds	that	could	be	synthesized	efficiently,	in	high	yields,	and	with	
potential	for	high	bioavailability.	We	selected	the	compound	atractylodinol,	which	has	been	
identified	as	having	potent	anti‐PRRSV	properties	(Li	et	al.,	2013;	Kraus	et	al.,	2016),	as	the	
basis	for	our	synthesis	strategy.	We	previously	synthesized	atractylodinol	and	
demonstrated	its	anti‐PRRSV	activity;	however	the	synthesis	route	was	inefficient	(Kraus	
et	al.,	2016).	In	the	current	study,	our	strategy	included	designing	an	efficient	synthesis	
route	to	produce	large	amounts	of	atractylodinol	and/or	atractylodinol	analogs	and	assess	
their	anti‐PRRSV	activity	in	MARC‐145	cells	and	in	porcine	macrophages.	In	total,	thirteen	
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compounds	were	synthesized	and	screened	for	anti‐PRRSV	activities	and	we	identified	six	
atractylodinol	analogs	with	potent	anti‐PRRSV	activity	in	vitro.		
	
2.	Materials	and	Methods	
	
2.1	Synthesis	of	atractylodinol	and	analogs	
The	synthesis	strategy	for	atractylodinol	is	summarized	in	Fig.	1A	and	detailed	in	an	
earlier	paper	(Kraus	et	al.,	2016).	The	original	compound	identified	by	(Li	et	al.,	2013),	
atractylodinol	(compound	1),	was	synthesized	in	seven	steps	from	butenynylfuran	(2)	and	
bromopentenynol	(4)	in	an	overall	yield	of	11%	(Fig	1A).	Because	of	the	low	overall	yield,	a	
second	synthetic	route	was	developed	via	ester	7,	which	was	synthesized	in	five	steps	from	
commercially	available	materials,	and	could	further	be	converted	to	atractylodinol	(1).	Due	
to	the	number	of	steps	and	the	modest	overall	yields,	neither	synthetic	route	was	feasible	
for	scale‐up.		In	the	present	study	we	synthesized	ten	additional	analogs	predicted	to	
increase	bioavailability,	stability	and/or	efficiency	of	synthesis	(Fig.	1B‐D).		Preliminary	
experiments	suggested	that	the	furan	enyne	subunit	was	important	for	activity	(not	
shown).	In	order	to	generate	compounds	bearing	this	subunit	in	high	yields,	dimers	8,	9,	10,	
and	12	were	prepared	(Fig	1b).		Analogs	8–	12	had	the	conjugated	bis‐enyne	skeleton	and	
were	more	polar	compounds	that	could	be	expected	to	have	greater	bioavailability.		The	
presence	of	the	amine,	or	its	corresponding	salts,	in	analog	9	may	further	increase	
bioavability.	The	analog	8	was	synthesized	by	dimerization	of	compound	2	in	36%	yield.		
Diamine	analog	9	and	aldehyde	analog	10	were	made	in	one	step	from	8	in	yields	of	60%	
and	33%,	respectively.	Additionally,	alcohol	analog	11	and	its	dimer,	diyne	12,	were	
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synthesized	in	yields	of	53%	and	52%,	respectively.	Analogs	13	and	14	were	benzene	ring	
analogs	of	7	and	8,	and	would	be	expected	to	be	more	stable	(Fig	1C).		Ester	13	and	dimer	
14	were	synthesized	from	3,4‐methylenedioxyphenylacetylene.		Truncated	analogs	15,	16,	
and	17	contained	segments	of	1,	and	were	each	prepared	in	one	step	from	2	(Fig	1D).		
All	synthesized	compounds	were	analyzed	by	1H	NMR,	13C	NMR	and	high	resolution	
mass	spectrometry	to	verify	their	structure.	Because	some	compounds	were	not	readily	
soluble	in	water,	all	compounds	were	solubilized	in	DMSO	at	a	concentration	of	1	mg/mL,	
and	further	dilutions	for	the	anti‐viral	and	cytotoxicity	assays	were	made	in	culture	media.		
	
2.2	Cells	and	virus		
MARC‐145	cells	were	used	for	anti‐viral	assays	and	were	maintained	in	high	glucose	
(4500mg/L)	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	(Sigma)	supplemented	with	
10%	FBS,	100	U/ml	penicillin,	100	μg/ml	streptomycin,	and	2	mM	L‐glutamine.	The	
porcine	alveolar	macrophage	cell	line,	ZMAC,	was	originally	established	from	lung	lavage	of	
porcine	fetuses	as	previously	described	(Calzada‐Nova	et	al.,	2012).	ZMAC	is	a	patented	cell	
line	and	we	obtained	the	cells	from	the	Aptimmune	Biologics	Inc.,	Champagne,	IL.	The	
ZMAC	cells	were	cultured	in	RPMI‐1640	medium	with	supplements	as	previously	described	
(Calzada‐Nova	et	al.,	2012).				
The	PRRSV	strain	NVSL97‐7895	(GenBank	accession	AY545985)	was	passaged	once	in	
MARC‐145	cells	and	used	in	all	assays.		
	
2.3	Antiviral	activity	of	synthetic	analogs	in	MARC‐145	cells	
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Compounds	were	assayed	for	anti‐PRRSV	activity	in	MARC‐145	cells	using	a	focus‐
reduction	assay	as	previously	described	(Wu	et	al.,	2011;	Evans	et	al.,	2017).	For	most	
assays,	10	g	of	each	compound,	or	DMSO	diluent	control,	were	incubated	with	varying	
amounts	of	PRRSV	NVSL97‐7895	for	1	hr	at	37°C	and	inoculated	in	duplicate	onto	MARC‐
145	cells	seeded	the	previous	day	at	3x105	cells/well	in	a	12‐well	plate.		At	24	hours	post	
infection,	cells	were	fixed	in	ice‐cold	methanol:acetone	and	immunocytochemistry	was	
performed	using	the	PRRSV	N	protein‐specific	monoclonal	antibody	SDOW17	(Rural	
Technology)	as	the	primary	antibody	and	sheep	anti‐mouse	IgG	conjugated	to	HRP	
(Jackson	ImmunoResearch)	as	the	secondary	antibody.	Following	addition	of	the	HRP	
substrate,	cells	were	rinsed	with	distilled	water,	air‐dried,	and	foci	of	infected	cells	were	
enumerated	by	light	microscopy.	Percent	virus	inhibition	was	calculated	as	a	reduction	in	
foci	as	compared	to	virus‐only	control	wells.	Assays	were	done	in	duplicate	and	repeated	at	
least	twice.	
To	determine	the	concentration	of	compound	capable	of	inhibiting	50%	of	input	
virus	(IC50),	three‐fold	serial	dilutions	of	active	compounds	were	incubated	with	200	FFU	
NVSL97‐7895	and	PRRSV	inhibition	was	assayed	using	the	focus‐reduction	assay	as	
described	above.		The	IC50	of	each	compound	was	calculated	from	replicate	assays	using	
normalized	inhibition	dose	response	linear	regression	in	GraphPad	Prism	7.	As	another	
measure	of	potency,	10	g	of	each	active	analog	were	incubated	with	10‐fold	serial	
dilutions	of	PRRSV	NVSL97‐7895,	ranging	from	2.5	X	102	to	2.5	X	105	FFU,	and	PRRSV	
inhibition	was	assayed	as	described	above.	Assays	were	done	in	duplicate,	repeated	twice,	
and	the	results	were	analyzed	by	one‐way	analysis	of	variance	(ANOVA)	using	GraphPad	
Prism	7	software.		
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2.4	Antiviral	activity	of	synthetic	analogs	in	porcine	macrophages		
The	porcine	macrophage	cell	line	ZMAC	(Calzada‐Nova	et	al.,	2012)	was	used	to	evaluate	
the	anti‐PRRSV	activity	of	lead	compounds.		For	these	assays,	10	g	of	select	compounds	or	
DMSO	diluent	control	were	incubated	with	200	FFU	NVSL97‐7895	(2.1	X	105	copies	viral	
RNA)	for	1	hr	at	37°C	and	inoculated	in	triplicate	onto	ZMAC	cells	seeded	at	2	x	105	
cells/well	in	24‐well	plates.	Cells	were	incubated	1	hr	at	37°C,	at	which	time	the	
supernatant	was	discarded	and	fresh	media	was	added.	Cells	were	incubated	for	an	
additional	16	hrs	at	37°C,	lysed	by	freeze‐thawing	and	centrifuged	at	3000	xG	for	10	min.	
Virion	RNA	was	isolated	from	the	supernatant	fraction	using	the	QIAamp	Viral	RNA	Mini	kit	
(Qiagen)	and	quantified	by	RT‐qPCR	using	primers	specific	for	PRRSV	ORF7	RNA.	Assays	
were	done	in	triplicate	and	repeated	twice.	
	
2.5	Cytotoxicity	assays	
Cytotoxicity	of	the	anti‐PRRSV	compounds	was	determined	using	an	ATP‐based	cell	
viability	assay	Cell	Titer	Glo™	(Promega).	To	assess	cytotoxicity	for	MARC‐145	cells,	
selected	analogs	were	serially	diluted	in	media	and	inoculated	in	triplicate	onto	MARC‐145	
cells	seeded	the	previous	day	at	2.5x	104	cells	per	well	in	a	96‐well	black	and	white	plate.	
Controls	included	media	only	and	DMSO.		Cells	were	incubated	at	37°C	overnight,	
equilibrated	at	room	temperature	for	30	min,	and	100	l	of	CellTiter‐Glo	reagent	was	
added	to	each	well.		The	plates	were	placed	on	an	orbital	shaker	for	2	min	to	induce	cell	
lysis	and	incubated	at	room	temperature	for	an	additional	10	min.		Luminescence	was	
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quantified	as	relative	light	units	(RLU)	using	Centro	XS3	LB960	Luminometer	(Berthold	
Technologies).		
To	assess	the	cytotoxicity	in	ZMAC,	select	analogs	were	serially	diluted	in	media,	
incubated	at	37°C	for	1	hour	and	added	to	duplicate	wells	of	ZMAC	cells	seeded	in	24‐well	
plates	at	2	X	105	cells/well	for	1	hour	at	37°C.		The	supernatant	was	replace	with	fresh	
media	and	cells	wells	were	incubated	for	16	hrs	at	37°C	and	equilibrated	at	room	
temperature	for	30	min.		One	hundred	l	of	CellTiter‐Glo	reagent	was	added	to	each	well	
and	cells	were	lysed	by	shaking	for	2	min.		The	plate	was	incubated	an	additional	10	min	at	
room	temperature	at	which	time	200	l	from	each	well	was	transferred	to	triplicate	wells	
of	96‐black	and	white	plate	and	luminescence	was	quantified	as	above.		
Cytotoxicity	was	calculated	as	the	RLU	in	treated	wells	as	compared	to	DMSO‐
treated	control	wells,	and	the	mean	of	replicates	was	reported.	The	50%	cytotoxic	
concentration	(CC50)	was	calculated	as	the	compound	concentration	that	reduced	the	
luminescence	by	50%,	using	normalized	inhibition	dose	response	linear	regression	in	
GraphPad	Prism	7.		
	
2.6	PRRSV	binding,	entry	and	replication	assays	
	 For	attachment	assays,	105	FFU	of	PRRSV	NVSL97‐7895	was	incubated	with	10	μg	of	
analog	or	DMSO	control	for	15	min	at	37°C.		The	sample	was	chilled	on	ice	and	inoculated	
onto	MARC‐145	cells	at	4°C	for	one	hour	to	facilitate	virion	attachment,	but	not	uptake	into	
the	cells.	After	incubation,	cells	were	washed	six	times	with	media	and	were	incubated	in	
300	l	PBS	containing	0.5%	trypsin	for	10	min.	Following	the	addition	of	50	l	FBS,	cells	
and	supernatant	were	collected	and	separated	by	centrifugation.	Virion	RNA	was	isolated	
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from	the	supernatant	fraction	using	the	QIAamp	Viral	RNA	Mini	kit	(Qiagen)	and	RNA	was	
quantified	by	RT‐qPCR	using	primers	specific	for	PRRSV	ORF7	RNA.	
For	entry	and	replication	assays,	PRRSV	was	incubated	with	analog	or	DMSO	and	
inoculated	onto	MARC‐145	cells	at	4°C	as	described	above.		Following	washing	to	remove	
unattached	virions,	fresh	media	was	added	and	the	cells	were	shifted	to	37°C,	designated	as	
time	0	hr.		At	1,	4,	8,	12,	or	24	hr,	cells	were	treated	with	trypsin	and	pelleted	by	
centrifugation	as	described	above,	and	total	RNA	was	isolated	from	the	cell	fraction	with	
the	RNeasy	mini	kit	(Qiagen).	Viral	RNA	was	quantified	by	RT‐qPCR	as	above.	All	assays	
were	done	in	duplicate	and	repeated	2‐3	times	and	results	are	reported	as	mean	copy	
number	of	viral	RNA/well.		A	student’s	t‐test	was	used	to	analyze	viral	copy	number	at	each	
time	point	across	virus‐only	and	analog‐treated	cells.		 	
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3.	Results	
3.1	Identification	of	small	molecule	compounds	with	anti‐PRRSV	activity		
Atractylodinol	isolated	from	rhizomes	of	Atractylodes	lancea	has	been	shown	to	
inhibit	PRRSV	replication	in	vitro	(Li	et	al.,	2013),	but	isolation	procedures	resulted	in	low	
yields	and	impurities.	To	overcome	the	limitations	of	isolation,	we	recently	described	a	
route	for	synthesis	of	atractylodinal	(Kraus	et	al.,	2016).	Synthetic	atractylodinol	and	two	
intermediate	compounds	(Fig	1A,	compounds	1,	2,	and	7)	were	found	to	have	potent	anti‐
PRRSV	activity;	however,	the	synthesis	routes	to	1	and	7	were	inefficient	and	not	feasible	
for	scale	up	to	the	quantities	of	material	needed	for	in	vivo	testing.		Analogs	such	as	2	were	
too	nonpolar	to	be	bioavailable.	In	the	present	study,	we	synthesized	ten	new	analogs	of	
atractylodinol	(Fig	1B‐D).	The	synthesis	routes	to	the	new	analogs	were	operationally	
convenient	and	would	permit	large‐scale	synthesis..		
	 For	initial	screening	assays	in	MARC‐145	cells,	10	μg	of	each	compound	was	
incubated	with	200	FFU	PRRSV	and	antiviral	activity	was	calculated	as	the	percent	
reduction	in	infectious	virus	as	compared	to	virus‐only	controls.	Consistent	with	our	
previous	report	(Kraus	et	al.,	2016),	atractylodinol	(1)	inhibited	100%	of	input	virus	(Fig.	
2A).	Additional	compounds	with	high	activity	were	structures	2,	7‐10	and	12.		Analogs	7‐
10	and	12	contain	the	furan‐substituted	bis‐enyne	subunit	(Fig	1).	Other	compounds	(13‐
17)	lacked	the	furan	substituent	or	the	complete	bis‐enyne	subunit	and	had	significantly	
reduced	activity,	indicating	the	presence	of	the	bis‐enyne	subunit	was	critical	for	optimal	
anti‐PRRSV	activity.		Based	on	these	promising	results,	atractylodinol	(1)	and	the	six	
analogs	with	>90%	PRRSV	inhibitory	activity	(2,	7‐10,	12)	were	selected	for	further	
characterization	in	MARC‐145	cells.	
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3.2	Potency	of	small	molecule	inhibitors	of	PRRSV		
To	determine	the	IC50	for	MARC‐145	cells,	serial	dilutions	of	each	active	compound	
were	incubated	with	200	FFU	of	virus	and	the	IC50	was	calculated	using	normalized	
inhibition	dose	response	linear	regression	in	GraphPad	Prism	7.	The	IC50	of	the	active	
compounds	ranged	from	392	nM	to	2.24	μM	(Table	1).		Atractylodinol	(1)	and	compound	2	
had	IC50	greater	than	1	μM,	while	the	other	five	compounds	had	IC50	in	the	nanomolar	
range	(Table	1).	All	seven	of	the	anti‐PRRSV	compounds	inhibited	PRRSV	in	a	dose‐
dependent	manner	(not	shown),	and	were	effective	at	concentrations	lower	than	that	
previously	reported	for	other	anti‐PRRSV	compounds	(Cheng	et	al.,	2013;	Gao	et	al.,	2013;	
Karuppannan	et	al.,	2012;	Zhao	et	al.,	2014).	The	IC50	of	synthetic	atractylodinol	(1)	was	
lower	than	that	reported	(Li	et	al.,	2013)	for	atractylodinol	isolated	from	plant	rhizomes	
(39.4	μM),	which	likely	is	due	to	differences	in	the	purity	of	the	material	tested	and/or	to	
differences	in	assay	conditions	used	to	evaluate	antiviral	activity.	Compound	2	was	the	
least	effective	of	the	seven	active	compounds,	with	a	maximum	PRRSV	inhibition	of	93.4%	
(Fig	2).		The	five	compounds	with	IC50	in	the	nanomolar	range	(7,	8,	9,	10,	12)	reached	
maximum	PRRSV	inhibition	of	97.2	to	100%	(Fig	2),		The	preparation	of	dimers	8,	9,	and	
12	requires	only	three	or	four	steps,	and	diamine	9	could	have	the	best	bioavailability.	
Thus,	compounds	8,	9,	and	12	were	considered	the	most	promising	leads	as	small	molecule	
inhibitors	of	PRRSV	replication.	
	
3.3	Cytotoxicity	of	small	molecule	inhibitors	of	PRRSV	
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To	evaluate	the	cytotoxicity	of	active	compounds,	MARC‐145	cells	were	treated	with	
serial	dilutions	of	each	active	compound	and	cytotoxicity	was	measured	using	the	Cell	Titer	
Glo™	assay.	The	concentration	of	compound	that	reduced	absorbance	by	50%	(CC50)	as	
compared	to	DMSO	control	was	calculated	for	each	compound	(Table	1).	Compound	1	was	
the	most	cytotoxic	among	the	seven	active	compounds,	with	only	a	9‐fold	difference	in	the	
CC50:IC50	ratio.	Compound	9	had	the	lowest	CC50	of	the	analogs	at	209	μM;	however,	this	
was	still	well	above	it’s	IC50	of	0.39	M,	resulting	in	a	CC50:IC50	ratio	of	535.	The	remaining	
active	compounds	had	CC50	ranging	from	558	to	1529	M,	with	CC50:IC50	ratios	greater	than	
1000.			
	
3.4	Atractylodinol	analogs	inhibit	high‐titers	of	PRRSV	
PRRSV	replicates	to	high	titers	in	vivo,	and	it	was	therefore	of	interest	to	evaluate	
the	effectiveness	of	small	molecule	inhibitors	in	the	presence	of	high‐titers	of	PRRSV.		To	
assess	this,	10	μg	of	each	compound	was	incubated	with	10‐fold	serial	dilutions	of	PRRSV	
ranging	from	105	to	102	FFU	and	percent	virus	inhibition	in	MARC‐145	cells	was	compared	
to	the	virus‐only	control	wells	(Fig	2B).	Each	of	the	compounds	maintained	a	similarly	high	
level	of	PRRSV	inhibition	at	all	virus	concentrations,	with	no	statistically	significant	
differences	in	inhibition	against	the	range	of	titers	tested.	Compounds	1	and	9	were	the	
most	active,	inhibiting	100	and	99.93%	of	input	PRRSV	up	to	105	FFU,	respectively.		
	
3.5	Compound	9	primarily	targets	a	post‐entry	step	of	PRRSV	replication	in	MARC‐
145	cells	
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To	investigate	the	mechanism	by	which	selected	compounds	inhibit	PRRSV,	we	
examined	the	early	steps	in	virus	replication	in	the	presence	of	one	of	the	small	molecule	
inhibitors.		Compound	9	was	chosen	for	these	assays	based	on	its	effectiveness	against	high	
concentrations	of	virus	(Fig	2B),	ease	of	synthesis,	and	potential	bioavailability.	MARC‐145	
cells	were	inoculated	with	105	FFU	PRRSV	in	the	presence	or	absence	of	10	g	compound	9,	
and	PRRSV	genomic	RNA	was	quantified	at	successive	steps	during	virus	replication.	We	
observed	a	small,	but	statistically	significant,	reduction	in	attached	virions	in	compound	9‐
treated	cells	compared	to	virus‐only	cells	(Fig	3,	time	0,	P=0.03).	Following	the	shift	to	37°C,	
viral	RNA	levels	decreased	through	4	hr	in	both	compound	9‐treated	and	control	cells,	
indicative	of	the	eclipse	phase	in	the	virus	replication	cycle.		Thereafter,	an	exponential	
increase	in	viral	RNA	occurred	in	the	virus‐only	cells,	starting	between	4‐8	hr	post‐entry.	In	
contrast,	the	increase	in	newly	synthesized	viral	RNA	was	delayed	in	compound	9‐treated	
cells,	and	there	was	significantly	less	PRRSV	RNA	detected	at	8,	12,	and	24	hr	post‐entry	as	
compared	to	the	virus‐only	cells	(P=0.018,	0.005,	and	<0.001,	respectively).	Although	there	
was	a	modest	inhibition	of	virion	attachment,	the	results	indicate	that	the	primary	
inhibitory	activity	of	compound	9	occurred	at	a	post‐entry	step	in	the	PRRSV	replication	
cycle.	
	
3.6	Antiviral	activity	and	cytotoxicity	of	lead	compounds	in	porcine	macrophages	
In	vivo,	PRRSV	replicates	in	porcine	alveolar	macrophages	(PAM);	therefore,	it	was	
important	to	determine	if	atractylodinol	analogs	would	inhibit	PRRSV	replication	in	the	
natural	host	cell.		Although	primary	PAM	cultures	can	be	established	in	vitro,	the	cultures	
are	short	lived	and	heterogeneity	within	and	between	different	cultures	confounds	
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reproducibility	of	experimental	results.	To	overcome	these	limitations,	we	assessed	the	
antiviral	activity	of	compounds	using	the	ZMAC	porcine	alveolar	macrophage	cell	line,	
which	was	originally	established	from	fetal	pig	lung	lavage	(Calzada‐Nova	et	al.,	2011;	
2012).	To	evaluate	anti‐viral	activity	in	ZMAC,	10	g	of	each	of	our	lead	compounds	(8,	9,	
12)	was	incubated	with	2.1	X	105	NVSL97‐7895	virions	(200	FFU)	in	100	l	for	1	hr	at	37°C	
and	inoculated	onto	ZMAC	cells	as	described	above.		After	16	hr,	cells	were	lysed	and	
PRRSV	RNA	was	isolated	and	quantified	by	qRT‐PCR.		Parallel	cultures	were	assayed	for	
viability	using	the	Cell	Titer	Glo™	assay.	Each	of	the	lead	compounds	was	shown	to	
significantly	reduce	PRRSV	replication	300‐2000	fold	in	ZMAC	cells	(Fig	4A).		Compounds	8	
and	12	were	most	effective	at	inhibiting	PRRSV	replication	ZMAC;	however,	we	observed	
~10%	reduction	in	cell	viability	of	ZMAC	in	the	presence	of	10	g	compound	12	as	
compared	to	DMSO	control	(Fig	4A).		The	CC50	of	compounds	8,	9,	and	12	in	ZMAC	was	277,	
266,	and	110	M,	respectively	(Fig	4B),	which	was	two‐	to	three‐fold	lower	than	we	
observed	in	MARC‐145	cells.	While	the	three	compounds	differed	in	their	relative	activity	
and	cytotoxicity	in	ZMAC	and	MARC‐145,	each	of	the	compounds	significantly	reduced	
PRRSV	replication	in	both	cell	types.	
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4.	Discussion	
PRRSV	is	one	of	the	most	economically	significant	swine	pathogens	worldwide.		
Over	the	last	three	decades,	efforts	to	control	PRRSV	have	met	with	some	success,	but	there	
is	an	urgent	need	for	new	strategies	to	augment	current	vaccine	and	biocontainment	
control	programs.		Natural	products	derived	from	plants	used	in	traditional	Chinese	
medicine	have	been	shown	to	have	anti‐PRRSV	activity	in	vitro	(Cheng	et	al.,	2013;	Gao	et	
al.,	2013;	Karuppannan	et	al.,	2012;	Li	et	al.,	2013;	Sun	et	al.,	2014;	Yang	et	al.,	2013;	Zhao	
et	al.,	2014),	and	we	previously	reported	the	synthesis	and	antiviral	activity	of	one	such	
compound,	atractylodinol	(Kraus	et	al.,	2016).	However,	the	synthetic	routes	were	largely	
inefficient	and	unlikely	to	be	cost‐effective	in	commercial	swine	operations.	In	the	present	
study,	we	synthesized	and	characterized	the	anti‐PRRSV	activity	of	atractylodinol	and	
twelve	additional	analogs.		Six	of	the	atractylodinol	analogs	were	found	to	be	potent	
inhibitors	of	PRRSV	replication	in	vitro,	with	IC50	in	the	0.4‐1.4	M	range.	Active,	but	not	
inactive,	analogs	contained	the	furan‐substituted	enyne	or	bis‐enyne	subunit,	
demonstrating	the	importance	of	this	subunit	for	anti‐PRRSV	activity.	Although	synthetic	
atractylodinol,	compound	1,	had	high	cytotoxicity,	the	other	six	compounds	were	much	less	
cytotoxic,	with	CC50	between	200	to	1500	M,	resulting	in	CC50:IC50	of	500‐2000.		
Importantly,	many	of	the	synthetic	analogs	were	effective	against	high	titers	of	infectious	
virus,	inhibiting	>90%	of	PRRSV	up	to	105	infectious	units	in	MARC‐145	cells	Based	on	
efficiency	of	synthesis,	high	yield,	and	potential	bioavailability,	three	lead	compounds	(8,	9,	
and	12)	were	identified	and	shown	to	reduce	PRRSV	replication	100‐1000‐fold	in	porcine	
macrophages	at	concentrations	showing	little	to	no	cytotoxicity.		Investigation	into	the	
mechanism	of	action	revealed	that	the	major	anti‐viral	effect	occurred	between	4	and	8	
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hours	post‐entry,	and	resulted	in	a	significant	reduction	and/or	delay	in	production	of	viral	
RNA	in	newly	infected	cells,	suggesting	that	a	post‐entry	step	is	targeted.	The	availability	of	
small	molecule	inhibitors	of	PRRSV	may	aid	efforts	to	curtail	PRRSV	replication	in	vivo	and	
reduce	economic	losses	in	the	swine	industry.	
In	vivo,	PRRSV	replicates	in	alveolar	macrophages,	and	it	was	important	to	ascertain	
the	effectiveness	of	the	analogs	in	a	relevant	cell	type.	ZMAC	cells,	which	were	originally	
established	from	fetal	pig	lung	lavage,	express	the	typical	macrophage	cell‐surface	markers	
such	as	CD14,	CD45,	CD163,	and	CD172,	and	are	highly	susceptible	to	PRRSV	infection	
(Calzada‐Nova	et	al.,	2011;	2012).		Each	of	the	three	lead	compounds,	8,	9,	and	12,	
significantly	reduced	PRRSV	replication	in	ZMAC	at	concentrations	with	little	to	no	
cytotoxicity.	Interestingly,	the	relative	effectiveness	and	cytotoxicity	of	the	lead	compounds	
depended	on	cell	type.	Compound	9	was	most	effective	in	reducing	PRRSV	replication	in	
MARC‐145	cells,	yet	also	had	the	lowest	CC50	of	the	analogs	tested	in	these	cells.		In	ZMAC	
cells,	however,	9	was	less	effective	than	8	and	12	in	inhibiting	PRRSV	replication,	but	was	
less	cytotoxic	than	compound	12,	the	most	cytotoxic	compound	for	ZMAC.	The	reasons	for	
these	cell‐type	specific	differences	are	not	clear.		Few	studies	of	small	molecule	inhibitors	
have	directly	compared	anti‐PRRSV	activity	in	MARC‐145	and	PAM.		In	one	study	(Yang	et	
al.,	2013),	flavispidic	acid	AB	(FA‐AB)	had	a	slightly	lower	EC50	in	MARC‐145	(3.5	g/ml)	
than	in	PAM	(4.2	g/ml);	however,	different	PRRSV	strains	were	used	in	each	cell	type	and	
it	is	not	clear	if	the	small	differences	in	activity	were	due	to	host	cell	and/or	virus	strain.	
We	observed	that	ZMAC	were	more	sensitive	than	MARC‐145	to	higher	concentrations	of	
atractylodinol	analogs.	Similarly,	Yang	et	al	(2103)	reported	that	the	antiviral	compound	
FA‐AB	was	more	cytotoxic	to	PAM	than	MARC‐145	cells.		It	is	not	clear	what	in	vitro	
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parameters	are	most	predictive	of	effectiveness	in	limiting	PRRSV	replication	in	pigs.	
However	the	overall	effectiveness	of	compound	8	and	9	in	reducing	PRRSV	replication	in	
ZMAC	at	concentrations	well	below	their	CC50	is	encouraging	and	warrants	further	studies	
evaluating	antiviral	activity	in	vivo.	
The	mechanism	of	action	of	atractylodinol	analogs	was	investigated	using	
compound	9,	which	was	selected	based	on	its	inhibition	of	high	titers	of	PRRSV	in	MARC‐
145	cells	(Fig	2B),	ease	of	synthesis,	and	potential	bioavailability.	Incubation	of	PRRSV	with	
compound	9	prior	to	infection	resulted	in	a	small,	but	significant	reduction	in	virion	
attachment	(Fig.	3).	Time	of	addition	studies	also	revealed	a	small,	but	significant	reduction	
in	antiviral	activity	when	compound	9	was	added	1‐3	hr	post‐infection	(not	shown).		
Together,	these	results	indicate	compound	9	may	inhibit	the	earliest	steps	in	PRRSV	
replication,	including	attachment	and	entry.		However,	the	major	inhibition	of	PRRSV	
replication	occurred	at	a	post‐entry	step	in	the	virus	replication	cycle.	Significant	inhibition	
in	levels	of	newly	synthesized	viral	RNA	was	observed	between	4	and	8	hours	post‐entry,	
when	there	was	exponential	increase	in	RNA	production	in	non‐treated	control	cells.	Viral	
RNA	levels	increased	in	compound	9	treated	cells	by	12	hpi;	however,	the	overall	levels	
remained	significantly	lower	than	in	virus‐only	cells,	representing	>99.8%	inhibition.	
Additional	studies	are	needed	to	determine	the	specific	mechanism(s)	of	PRRSV	inhibition,	
but	possible	targets	include	inhibition	of	virus	uncoating	and/or	synthesis	of	viral	RNA.	It	is	
also	possible	that	antiviral	activity	is	due	in	part	to	induction	of	innate	antiviral	response	
(Yang	et	al.,	2013).	
A	number	of	studies	have	identified	compounds	with	anti‐PRRSV	activity	in	vitro.	
These	are	primarily	comprised	of	natural	products	derived	from	plants	used	in	traditional	
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Chinese	medicine	(Cheng	et	al.,	2013;	Gao	et	al.,	2013;	Karuppannan	et	al.,	2012;	Li	et	al.,	
2013;	Sun	et	al.,	2014;	Yang	et	al.,	2013;	Zhao	et	al.,	2014).	It	is	difficult	to	directly	compare	
antiviral	activities	of	compounds	across	in	vitro	studies,	due	in	part	to	the	variation	in	
protocols	to	assay	virus	inhibition,	the	use	of	whole	extracts	versus	purified	compounds,	
and	differences	in	the	method	of	reporting	IC50	(μg/ml	vs.	μM).	Most	of	the	anti‐PRRSV	
compounds	previously	described	had	IC50	in	the	range	of	<1	to	98	μM.		When	reported,	CC50	
were	in	the	range	of	94	to	431	μM,	with	varying	levels	of	inhibition	and	potency	(Cheng	et	
al.,	2013;	Gao	et	al.,	2013;	Karuppannan	et	al.,	2012;	Zhao	et	al.,	2014).	Our	synthetic	
compounds	had	equivalent	or	somewhat	lower	IC50		(392	nM	to	2.24	μM)	and	were	
generally	less	toxic	in	MARC‐145	cells	(CC50	~200‐1500	μM,	Table	1).	The	optimal	levels	of	
antiviral	activity	needed	to	reduce	PRRSV	replication	in	vivo	are	not	known,	and	to	date	
only	one	study	has	examined	the	effectiveness	of	PRRSV	antivirals	in	vivo	(Gao	et	al.,	2013).	
It	is	interesting	to	note,	however,	that	all	six	of	the	analogs	had	higher	potency	and	lower	
IC50	in	vitro	than	that	reported	for	extracts	of	Cryptoporus	volvatus,	which	was	found	to	
reduce	PRRSV	replication	and	associated	clinical	signs	in	vivo	(Gao	et	al.,	2013).		It	is	
important	to	note	that	higher	concentrations	of	the	Cryptoporus	volvatus	were	likely	
required	because	it	was	a	naturally	derived	mushroom	extract	rather	than	a	homogenous	
synthetic	compound.	Nevertheless,	these	results	provide	promising	evidence	that	anti‐
PRRSV	activity	in	vitro	can	translate	to	PRRSV	inhibition	in	vivo.	
In	developing	a	drug	for	animal	health,	there	is	a	necessary	balance	between	the	
level	of	a	compound’s	antiviral	activity,	its	bioavailability	and	the	cost	of	preparing	the	
compound.	Our	synthesis	strategy	considered	both	the	ease	of	synthesis	and	potential	for	
bioavailability.	Dimers	8,	9,	and	12	can	be	prepared	in	only	three	or	four	steps,	while	9	or	
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its	salts	may	have	the	best	bioavailability.	Based	on	CC50	in	ZMAC	and	overall	effectiveness	
in	both	cell	types,	compounds	8	and	9		may	be	the	most	promising	lead	candidates	for	
future	in	vivo	trials.	There	are	several	concerns	and	hurdles	regarding	the	use	of	antivirals	
in	food	animals,	including	the	cost	of	treatment	and	potential	for	persistence	of	antivirals	in	
the	food	chain.		However,	targeted	and/or	temporary	administration	of	potent	antivirals	
could	be	one	component	incorporated	into	a	multi‐pronged	PRRSV‐control	strategy	to	
lessen	the	economic	burden	of	PRRSV	infection.	The	relatively	high	and	sustained	level	of	
PRRSV	inhibition	suggests	that	compound	8,	9	or	similar	small	molecule	inhibitors	may	be	
especially	useful	in	limiting	PRRSV	spread	during	outbreaks	and/or	during	periods	of	high	
PRRSV	susceptibility.		
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7.	Figure	Legends	
	
Figure	1.	Synthesis	routes	for	atractylodinol	and	analogs.		A)	Previously	described	(Kraus	
et	al.,	2017)	routes	for	synthesis	routes	for	synthetic	atractylodinol	(1).		B)	Analogs	
containing	the	conjugated	bis‐enyne	skeleton;	C)	Benzene	ring	containing	analogs;	D)	
Analogs	prepared	in	one	step	from	compound	2.	
	
Figure	2.	Anti‐PRRSV	activity	of	synthetic	atractylodinol	(1)	and	related	analogs.	A.	Ten	μg	
of	each	compound	were	incubated	with	2x102	FFU	PRRSV	1	hr	at	37°C	and	inoculated	onto	
MARC‐145	cells.	Percent	virus	inhibition	represents	the	reduction	in	PRRSV	FFU	compared	
to	virus‐only	control	cells.	Assays	were	done	in	duplicate	and	error	bars	represent	mean	
±standard	deviation	of	replicate	assays.		B.	Serial	ten‐fold	dilution	of	PRRSV	from	105	to	102	
FFU	were	incubated	with	10	μg	compounds	and	inoculated	onto	MARC‐145	cells.	Percent	
virus	inhibition	represents	the	reduction	in	PRRSV	FFU	compared	to	virus‐only	control	
wells.	Means	from	two	independent	experiments	are	reported.	Error	bars	represent	
±standard	deviation	of	the	means.	No	statistically	significant	differences	between	virus	
treatments	within	compound	were	detected	via	one‐way	ANOVA.	
	
Figure	3.		Compound	9	inhibits	a	post‐entry	step	in	PRRSV	replication.	Results	are	
reported	as	the	average	RNA	copy	number	per	well	as	determined	by	RT‐qPCR.		Bound	
indicates	attached	virions	after	1	hr	incubation	at	4°.	Arrow	indicates	shift	of	cells	to	37°C.	
Times	1,	4,	8,	12,	and	24	hpi	represents	cell‐associated	RNA	copy	number	at	sequential	
times	following	shift	to	37°C.	Asterisks	represent	statistically	significant	differences	
between	virus‐only	and	compound‐treated	cells	as	determined	by	a	t‐test	(P<0.05).	
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Figure	4.		Antiviral	activity	and	cytotoxicity	of	lead	compounds	in	porcine	macrophages.		
A.		Viral	RNA	copy	number	(black	bars)	in	ZMAC	cells	at	16	h	post‐infection	with	PRRSV	
treated	with	media	only,	DMSO	or	10	g	of	compound	8,	9,	or	12.		Grey	bars	indicate	
percent	cytotoxicity	in	parallel	cultures.		Results	represent	the	mean	of	replicate	
experiments	done	in	triplicate	±	SEM.		*P<0.001.		B.		Cytotoxicity	of	lead	compounds	8,	9,	
and	12	in	ZMAC	cells	determined	using	ATP‐based	Cell	Titer	Glo™	assay.		Dotted	line	
indicates	50%	reduction	in	RLU	as	compared	to	cells	treated	with	DMSO	control.		Results	
represent	the	mean	±	SEM	of	replicate	treatments	assayed	in	triplicate.	
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Table	1.		Potency	and	cytotoxicity	of	small	molecule	inhibitors	of	PRRSV	
	
Compound	 IC50	(M)	 CC50	(M)	 CC50/IC50	Mean	 95%	CI	 Mean	 95%	CI	
1	 2.24	 1.65	‐	3.03	 21	 18	‐	25	 9	
2	 1.42	 1.11	‐	1.81	 1547	 1325	‐	2894	 1087	
7	 0.50	 0.36	‐	0.68	 769	 733	‐	814	 1532	
8	 0.55	 0.40	‐	0.75	 566	 533	‐	605	 1025	
9	 0.39	 0.33	‐	0.47	 209	 192	‐	229	 533	
10	 0.45	 0.37	‐	0.55	 1113	 909	‐	2522	 2473	
12	 0.59	 0.42	‐	0.83	 697	 627	‐	790	 1183	
	 	 	 	 	 	 	 	
	
	
